Biogen Inc. (BIIB) Dropped To A 2-Month Low On Phase 2 Study Results

Biogen Inc. (BIIB) announced Tuesday morning that its Phase 2 study of opicinumab missed the primary endpoint in patients with relapsing forms of multiple sclerosis.

from RTT - Before the Bell http://ift.tt/1t8v17q
via IFTTT